Mr Eugene Cheng

Biography

Mr. Cheng leads the development of TBG Diagnostics Limited (TDL) as the COO of the company. Mr Cheng is also the Chief Executive Officer (CEO) of TBG Taiwan and TBG Xiamen. Mr. Cheng joined Medigen Biotechnology Corp in 2004 and initiated the molecular diagnostics business in 2006 by the acquisition of Texas Biogene, Inc. (TBG), a biotech company based in Dallas, USA, specializing in the development of tissue typing products that are marketed under the TBG brand. Mr. Cheng also spearheaded the acquisition of Haoyuan in Shanghai, China, in 2007, and its divestiture to Perkin Elmer in 2012 when Haoyuan became the leading local brand in the NAT blood screening market in China. Armed with the knowledge and experience in the Chinese market, TBG aims to become one of the leading molecular diagnostics brands in China within 5 years. As part of the strategy to achieve that goal, TBG was re-listed on ASX through a reverse merger with Progen Pharmaceutical (PGL) in February 2016. Currently, Mr. Cheng serves as a director of both Medigen and TDL.

Research Interest

Business, Management, Toxicology, Pharmacology, Drug Discovery